The Nutrition cluster is made up of DSM Nutritional Products and DSM Food Specialties. DSM Nutritional Products is one of the world’s leading producers of essential nutrients such as vitamins, carotenoids, nutritional lipids and other ingredients to the feed, food, pharmaceutical and personal care industries. DSM Food Specialties’ food enzymes, cultures, yeast extracts, savory flavors, hydrocolloids and other specialty ingredients are found in the world’s favorite dairy, baking, beverage and savory brands.
The Materials cluster is made up of DSM Engineering Plastics, DSM Dyneema and DSM Resins & Functional Materials. DSM Engineering Plastics is a global player in specialty plastics. These materials are used in components for the electrical and electronics, automotive, flexible food packaging and consumer goods industries. DSM Dyneema is the inventor, manufacturer and marketer of Dyneema®, the world’s strongest fiber™. DSM Resins & Functional Materials is a global producer of innovative, sustainable resins solutions for paints and industrial and optical fiber coatings.
Besides supporting innovation in our core businesses and venturing activities, the DSM Innovation Center also aims to develop its Emerging Business Areas (EBAs). They comprise DSM Biomedical, focused on innovative materials for medical devices; DSM Bio-based Products & Services, which focuses on clean energy from crop residues as well as bio-chemicals with enzymes and yeasts for biomass conversion; and DSM Advanced Solar, which offers yield-boosting solutions for solar energy.
As part of its 2010-2015 strategy, DSM established partnerships for its Pharma activities (DSM Sinochem Pharmaceuticals for anti-infectives in 2011 and Patheon for contract development and manufacturing services in 2014), and for the remaining Bulk Chemical businesses in Polymer Intermediates and Composite Resins (ChemicaInvest in 2015).
On 29 August 2017 DSM confirmed Thermo Fisher Scientific Inc. completed the acquisition of Patheon. Together with the approximately €0.5 billion in cash that DSM already received in recent years, including the proceeds from the Initial Public Offering of Patheon, the total cash proceeds from the divestment of DSM’s custom manufacturing activities in Pharma in 2014 amount to approximately €2.0 billion.